WO2012147556A1 - 亜リン酸デヒドロゲナーゼタンパク質の製造方法およびその利用 - Google Patents
亜リン酸デヒドロゲナーゼタンパク質の製造方法およびその利用 Download PDFInfo
- Publication number
- WO2012147556A1 WO2012147556A1 PCT/JP2012/060293 JP2012060293W WO2012147556A1 WO 2012147556 A1 WO2012147556 A1 WO 2012147556A1 JP 2012060293 W JP2012060293 W JP 2012060293W WO 2012147556 A1 WO2012147556 A1 WO 2012147556A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- phosphite dehydrogenase
- producing
- host
- seq
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y120/00—Oxidoreductases acting on phosphorus or arsenic in donors (1.20)
- C12Y120/01—Oxidoreductases acting on phosphorus or arsenic in donors (1.20) with NAD+ or NADP+ as acceptor (1.20.1)
- C12Y120/01001—Phosphonate dehydrogenase (1.20.1.1)
Definitions
- the present invention relates to a method for producing a phosphite dehydrogenase protein and use thereof. More specifically, the present invention relates to a method for producing a phosphite dehydrogenase protein, a method for producing NADH, and a method for producing NADPH.
- the phosphite dehydrogenase protein is a protein possessed by a part of bacteria, and is an enzyme that oxidizes phosphorous acid in an NAD + dependent or NADP + dependent manner to produce NADH or NADPH.
- the reaction formula in the case of oxidizing phosphorous acid depending on NAD + or NADP + is described below.
- phosphite dehydrogenase has the advantages that both the substrate and the product are low in reactivity and the substrate is inexpensive, so if it can be used industrially, It has the potential to be widely used instead. Specifically, in the case of phosphite dehydrogenase, since both phosphorous acid and phosphoric acid have a buffering action, it is possible to stabilize the reaction system.
- Non-Patent Document 3 discloses a technique for increasing the amount of mutant phosphite dehydrogenase protein contained in a soluble fraction by forcibly expressing a phosphite dehydrogenase protein into which a mutation has been introduced in E. coli. It is disclosed. From the data described in Non-Patent Document 3, the reason why the amount of mutant phosphite dehydrogenase protein contained in the soluble fraction has increased is because the solubility of the protein has increased, It cannot be determined whether the expression level of the protein has increased.
- Non-patent documents 4 and 5 disclose mutant phosphite dehydrogenase proteins with high thermal stability.
- the present invention has been made in view of the above-described conventional problems, and an object thereof is to provide a method for producing a phosphite dehydrogenase protein having both improved solubility and thermal stability properties and use thereof There is to do.
- the present inventors have completed the present invention by isolating phosphite dehydrogenase having improved both stability and solubility properties from the natural world by an original screening method.
- the protein of the present invention is a protein described in the following (a) or (b).
- (A) A protein consisting of the amino acid sequence of SEQ ID NO: 1.
- (B) a protein consisting of amino acids in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 1 and having phosphite dehydrogenase activity;
- the present invention produces an effect that a large amount of a phosphite dehydrogenase protein having high solubility in an aqueous solution can be obtained.
- the present invention has an effect that a large amount of phosphite dehydrogenase protein having high heat resistance can be obtained.
- the present invention has an effect that a large amount of phosphite dehydrogenase protein whose activity is not inhibited by various inhibitors can be obtained.
- the present invention has an effect that a large amount of phosphite dehydrogenase protein having higher reaction efficiency than that of conventional phosphite dehydrogenase protein can be obtained.
- 2 is a photograph of SDS-PAGE showing the location of a phosphite dehydrogenase protein when the phosphite dehydrogenase protein of the present invention is forcibly expressed in E. coli. It is a graph which shows the heat resistance of the phosphite dehydrogenase protein of this invention. It is a graph which shows the effect of various inhibitors on the activity of the phosphite dehydronase protein of this invention.
- the protein of the present embodiment is a protein described in the following (a) or (b).
- amino acids in which one or several amino acids have been deleted, substituted, or added will be described later.
- the protein of this embodiment has a homology of 85.0% or more, more preferably 90.0% or more, more preferably 95.0% or more, more preferably 98.0% or more with the amino acid sequence of SEQ ID NO: 1. It may be a protein having an amino acid sequence having sex and having phosphite dehydrogenase activity.
- the protein of the present embodiment is a protein having extremely excellent properties such as high solubility in an aqueous solution and high heat resistance.
- the gene of the present embodiment is a gene encoding the protein described in (a) or (b) above.
- the gene of the present embodiment only needs to encode the above protein, and may be a gene formed by any combination of codons.
- the gene of the present embodiment may be a gene comprising the following DNA (c) or (d).
- the method for producing a phosphite dehydrogenase protein of the present embodiment comprises the steps of expressing the following protein (a) or (b) in a host and solubilizing the protein expressed in the host in a solution: And a manufacturing method.
- B a protein consisting of amino acids in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 1 and having phosphite dehydrogenase activity;
- the above-mentioned protein consisting of the amino acid sequence of SEQ ID NO: 1 is a phosphite dehydrogenase protein obtained by screening by the present inventor (see Examples).
- the protein expressed in the host may be a protein consisting of amino acids in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 1 and having phosphite dehydrogenase activity.
- the site where one or several amino acids are deleted, substituted or added is not particularly limited, and the protein after one, several amino acids are deleted, substituted or added has phosphite dehydrogenase activity. As long as it has, it may be any site in the protein.
- the number of amino acids intended by “one or several amino acids” is not particularly limited, but is preferably within 10 amino acids, more preferably within 8 amino acids, and within 6 amino acids. Most preferably.
- the protein expressed in the host is 85.0% or more, more preferably 90.0% or more, more preferably 95.0% or more, more preferably 98.0% or more of the amino acid sequence of SEQ ID NO: 1. It may be a protein having an amino acid sequence having homology and having phosphite dehydrogenase activity.
- the homology of amino acid sequences can be determined by a known method. Specifically, GENETYX-WIN (manufactured by GENETICS Co., Ltd.) is used in accordance with the GENETYX-WIN manual, and the amino acid sequence shown in SEQ ID NO: 1 and the amino acid sequence to be compared are matched by homology search Homology can be calculated as a percentage of the amino acid sequence to be.
- GENETYX-WIN manufactured by GENETICS Co., Ltd.
- the protein expressed in the host may be a fusion protein of the above-described protein and another protein or tag.
- the other protein and tag are not particularly limited, and a desired protein (for example, GST protein) or a tag (for example, His tag, HA tag, Flag tag, etc.) can be used.
- the method for producing a phosphite dehydrogenase protein includes a step of expressing the above-described protein in a host.
- the host is not particularly limited, and a desired host can be used as appropriate.
- bacteria such as Escherichia coli (for example, Escherichia coli), yeast (for example, budding yeast Saccharomyces cerevisiae, fission yeast Schizosaccharomyces pombe, etc.), insect cells, nematodes (for example, Caenorhabditis elegans, for example, X. Etc.) oocytes, mammalian cells (for example, CHO cells, COS cells, and Bowes melanoma cells), various human cultured cells, and the like, but are not limited thereto.
- the step of expression is not particularly limited as long as the protein of (a) or (b) can be expressed in the host.
- the step of expressing can include a step of introducing a vector containing a DNA comprising a base sequence encoding the protein of (a) or (b) into a host.
- the specific base sequence of the DNA is not particularly limited, and various codon sequences can be used for each amino acid in the protein.
- the DNA can be, for example, the following DNA (c) or (d). In other words, (C) DNA consisting of the base sequence of SEQ ID NO: 2.
- the above-mentioned DNA consisting of the base sequence of SEQ ID NO: 2 is a phosphite dehydrogenase gene obtained by screening by the present inventor and encoding a protein consisting of the above-mentioned amino acid of SEQ ID NO: 1. .
- the DNA contained in the vector may be a DNA that hybridizes with a base sequence complementary to the DNA consisting of the base sequence of SEQ ID NO: 2 under stringent conditions and encodes a phosphite dehydrogenase protein. .
- stringent conditions refers to hybridization solutions (50% formamide, 5 ⁇ SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7). .6) Incubate overnight at 42 ° C. in 5 ⁇ Denhart solution, 10% dextran sulfate, and 20 ⁇ g / ml denatured sheared salmon sperm DNA, then in 0.1 ⁇ SSC at about 65 ° C.
- the washing conditions at high stringency can be changed as appropriate. For example, when using mammalian-derived DNA, 0.1% SDS containing 0.1% SDS is used.
- washing at 65 ° C. in 5 ⁇ SSC (preferably 15 minutes ⁇ 2 times) is preferred.
- washing at 68 ° C. in 0.1 ⁇ SSC containing 0.1% SDS (preferably 15 minutes ⁇ 2 times) is preferable, and when using RNA, 0.1% Washing at 68 ° C. in 0.1 ⁇ SSC containing SDS (preferably twice for 15 minutes) is preferable, and when using oligonucleotide, in 0.1 ⁇ SSC containing 0.1% SDS Washing at the hybridization temperature (preferably 15 minutes ⁇ 2 times) is preferred.
- the above hybridization was performed by Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d Ed. , Cold Spring Harbor Laboratory (1989).
- the vector containing a DNA consisting of a base sequence encoding the protein (a) or (b) is not particularly limited and can be appropriately selected depending on the host.
- the vector can contain an expression control region (for example, a promoter, a terminator, and / or an origin of replication) depending on the host to be introduced.
- the promoter include viral promoters (for example, SV40 early promoter, SV40 late promoter, etc.) and the like.
- the promoter may be an expression-inducible promoter capable of inducing expression by IPTG or the like.
- the vector preferably contains at least one selectable marker.
- selectable markers include ampicillin, dihydrofolate reductase, neomycin resistance gene and the like.
- the method for introducing the vector into the host is not particularly limited, and a known method can be used as appropriate.
- conventionally known methods such as an electroporation method, a calcium phosphate method, a liposome method, and a DEAE dextran method can be suitably used.
- a method of introducing a recombinant DNA in the presence of calcium ions or a method using an electroporation method can be applied.
- the step of solubilizing the protein expressed in the host can include a step of crushing the host expressing the protein in a solution.
- the step of solubilizing the protein expressed in the host may include a step of centrifuging the crushed material in addition to the step of crushing the host expressing the protein in a solution.
- the solution for disrupting the host is not particularly limited.
- a surfactant for example, Tween-20 (registered trademark), Triton-X100 (registered trademark), SDS, or the like
- NaCl NaCl
- It can be a solution containing.
- the concentration of the surfactant in the solution is not particularly limited. For example, it is preferably 0 (w / v) or more than 0 (w / v) and 1.0% (w / v) or less. w / v) or more than 0 (w / v) and more preferably 0.5% (w / v) or less, more preferably 0 (w / v) or more than 0 (w / v) 0.3 % (W / v) or less, more preferably 0 (w / v) or more than 0 (w / v) and 0.1% (w / v) or less, more preferably 0 (w / V) or more than 0 (w / v) and most preferably 0.01% (w / v) or less.
- the lower limit value of the numerical range described above may be 0.01% (w / v) or 0.001% (w / v).
- the protein expressed in the host is originally highly soluble in the solution. Therefore, even a surfactant with a low concentration can be sufficiently solubilized in a solution.
- Surfactant may inhibit various chemical reactions. For example, when a surfactant is present, a chemical reaction may be inhibited when NADH or NADPH is produced using a phosphite dehydrogenase protein.
- the concentration of the surfactant for solubilizing the phosphite dehydrogenase protein may be low, so that it is mixed in the produced phosphite dehydrogenase protein.
- the amount of the surfactant can be kept low. As a result, when producing NADH or NADPH using the produced phosphite dehydrogenase protein, a large amount of NADH or NADPH can be produced efficiently.
- the concentration of NaCl in the solution is not particularly limited. For example, it is preferably 0 mM or more than 0 mM and 150 mM or less, more preferably 0 mM or more than 0 mM and 100 mM or less, and more preferably 0 mM or more than 0 mM and 50 mM. More preferably, it is 0 mM or more than 0 mM and 40 mM or less, more preferably 0 mM or more than 0 mM and 20 mM or less, more preferably 0 mM or more than 0 mM and 10 mM or less. More preferably, it is most preferably 0 mM.
- the lower limit value of the numerical range described above may be 0.01 mM or 0.001 mM.
- the protein expressed in the host is originally highly soluble in the solution. Therefore, even a low concentration of NaCl can be sufficiently solubilized in the solution.
- NaCl has an effect of inhibiting the activity of phosphite dehydrogenase protein. Therefore, it can be said that it is preferable to solubilize the phosphite dehydrogenase protein in a solution in which the concentration of NaCl is reduced as much as possible. Since conventional phosphite dehydrogenase has low solubility, a high concentration of NaCl was used in addition to the surfactant to solubilize the protein.
- the concentration of NaCl for solubilizing the phosphite dehydrogenase protein may be low, so that it is mixed in the produced phosphite dehydrogenase protein.
- the amount of NaCl can be kept low.
- the pH of the above solution can be adjusted with a known buffer.
- the buffer is not particularly limited, and any buffer having a sufficient buffer capacity in a pH range of 6.0 to 8.5 can be used. Buffers in this pH range include phosphate, tris, bis-trispropane, N-tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 2-morpholinoethanesulfonic acid monohydrate (MES), piperazine-1,4-bis (2-ethanesulfonic acid) (PIPES), 2- [4- (2-hydroxyethyl) -1 -Piperazinyl] ethanesulfonic acid (2- [4- (2- (2-Hydroxyethyl) -1-piperazinyl] ethanesulfonic acid) (HEPES), and 3- [N-tris (hydroxymethyl) methylamino] -2-hydroxypropanesulfonic acid (TAPSO).
- the method for producing a phosphite dehydrogenase protein according to this embodiment can include a step of heating a host expressing the protein or a crushed material of the host expressing the protein.
- the phosphite dehydrogenase protein of this embodiment has high heat resistance. Therefore, by the heating step, it is possible to lose the activity of other unnecessary enzymes without losing the activity of phosphite dehydrogenase. That is, it is possible to prevent unwanted enzyme activity from being mixed into the phosphite dehydrogenase obtained by the production method of the present embodiment.
- the specific method for performing the said heating process is not specifically limited, For example, it is possible to heat the culture solution containing the host which is expressing protein, and culture
- heating step it is preferable to heat a host expressing the protein or a crushed product of the host expressing the protein to 35 ° C. to 55 ° C., and to 40 ° C. to 52.5 ° C. Heating is more preferable, heating is preferably performed at 40 ° C to 50 ° C, and most preferably heating is performed at 40 ° C to 45 ° C.
- the heating time is not particularly limited, for example, it is preferably 0 minutes to 60 minutes, and more preferably 15 minutes to 30 minutes.
- the expressed phosphite dehydrogenase protein and a protease inhibitor are preferably allowed to coexist. According to the said structure, even if a protease exists, it can prevent that a phosphite dehydrogenase protein is decomposed
- the protease inhibitor is not particularly limited, and a known protease inhibitor can be appropriately used.
- the protease inhibitor include low molecular weight inhibitors (eg, diisopropylfluorophosphate, phenylmethanesulfonyl fluoride, p-mercuribenzoic acid, iodoacetic acid, diazoacetyl-DL-norleucine methyl ester, phosphoramide, etc.), peptides Examples include, but are not limited to, sex inhibitors (eg, leupeptin, antipain, chymostatin, pepstatin, etc.) and proteinaceous inhibitors (eg, ⁇ 2 macroglobulin, calpastatin, etc.).
- the method for producing NADH of this embodiment is a reaction between HPO 3 2- , NAD + and H 2 O using the phosphite dehydrogenase protein produced by the method for producing phosphite dehydrogenase protein of the present invention as an enzyme. It is a method to make it.
- reaction formula 1 see (Reaction formula 1) in the [Background Art] column.
- the NADPH production method of the present embodiment is a reaction of HPO 3 2- , NADP + and H 2 O using the phosphite dehydrogenase protein produced by the production method of phosphite dehydrogenase protein of the present invention as an enzyme. It is a method to make it.
- reaction formula 2 see (Reaction formula 2) in the [Background Art] column.
- the temperature at which the above reaction is performed is not particularly limited, but is preferably 35 ° C. to 55 ° C., more preferably 40 ° C. to 52.5 ° C., and further preferably 40 ° C. to 50 ° C. Preferably, it is 40 ° C to 45 ° C.
- the optimum temperature of the phosphite dehydrogenase protein produced by the method for producing a phosphite dehydrogenase protein of the present invention is much higher than that of a conventional phosphite dehydrogenase. Therefore, according to the above configuration, a large amount of NADH or NADPH can be efficiently manufactured.
- reaction temperature is high, even if an unnecessary enzyme is mixed in the reaction system, only the activity of the mixed unnecessary enzyme can be lost.
- the temperature when adjusting the reaction system to the above temperature, the temperature may be adjusted by applying temperature to the reaction system from the outside, but the temperature is adjusted by the reaction heat generated as the chemical reaction proceeds. May be. That is, if the phosphite dehydrogenase protein produced by the method for producing a phosphite dehydrogenase protein of the present invention is used, there is an advantage that it is not necessary to cool the reaction system.
- the above reaction can also be carried out in the presence of arsenite, nitrate, sulfate or NaCl.
- the activity of conventional phosphite dehydrogenases is greatly reduced by the presence of arsenite, nitrate, sulfate or NaCl.
- the activity of the phosphite dehydrogenase protein produced by the method for producing a phosphite dehydrogenase protein of the present invention is not significantly reduced even in the presence of arsenite, nitrate, sulfate or NaCl. . Therefore, the NADH or NADPH production method of the present embodiment can efficiently produce NADH or NADPH even if arsenite, nitrate, sulfate, or NaCl is present.
- the concentration of arsenite, nitrate, sulfate or NaCl in the reaction system is not particularly limited. For example, it is preferably 100 mM or less, more preferably 70 mM or less, further preferably 50 mM or less, although it is most preferable that it is 40 mM or less, it is not limited to these.
- the lower limit is not particularly limited, but may be 0.1 mM, 0.01 mM, or 0 mM.
- kit for producing NADH or NADPH The kit of this embodiment is a kit for producing NADH or NADPH.
- the kit of this embodiment may include a protein produced by the method for producing a phosphite dehydrogenase protein of the present invention. Moreover, the kit of this embodiment may include a vector for expressing the phosphite dehydrogenase protein of the present invention in a desired host. Since the details of these configurations have already been described, the description thereof is omitted here.
- the gene of the present invention is a gene encoding the protein of the present invention.
- the gene of the present invention may be a gene comprising the following DNA (c) or (d).
- the method for producing a phosphite dehydrogenase protein of the present invention can have a step of expressing the protein of the present invention in a host and a step of solubilizing the protein expressed in the host in a solution.
- the step of expressing may include a step of introducing a vector containing the gene of the present invention into a host.
- the solubilizing step may be performed by setting the host expressing the protein to 0 (w / v) or more than 0 (w / v) to 0.1%
- the step of crushing in a solution containing (w / v) or less surfactant and at least one of 0 (w / v) or NaCl of greater than 0 (w / v) and not more than 50 mM may be included.
- the surfactant may be Tween-20 or Triton-X100.
- the method for producing a phosphite dehydrogenase protein of the present invention can include a step of heating a host expressing the protein or a crushed material of the host expressing the protein.
- the host expressing the protein or a crushed product of the host expressing the protein is heated to 40 ° C. to 50 ° C. It may be a process to do.
- the above reaction can be performed at 40 ° C. to 50 ° C.
- the above reaction may be performed in the presence of arsenite, nitrate, sulfate or NaCl.
- MOPS agar medium 0.5 mM phosphate, 22.2 mM glucose, 40 mM potassium morpholine sulfate [pH 7.2], 50 mM NaCl, 9 mM containing 0.5 mM phosphorous acid.
- MOPS agar medium containing 2 mM phosphoric acid and MOPS agar medium not containing phosphorous acid and phosphoric acid were inoculated and cultured at 45 ° C. for 1 to 3 days. Thereafter, a plurality of microbial colonies that appeared on the MOPS agar medium containing 0.5 mM phosphorous acid were isolated.
- microorganisms forming each colony were cultured using a MOPS liquid medium containing 0.5 mM phosphorous acid, and each microorganism was examined to determine whether it had phosphite dehydrogenase activity.
- Each microorganism cryopreserved in a glycerol solution was inoculated into 4 mL of 2 ⁇ YT liquid medium and cultured at 45 ° C. overnight. 1 mL of the culture solution was put into a 1.5 mL capacity tube, and the tube was centrifuged at 12000 rpm for 5 minutes, and then the supernatant was discarded to obtain a cell pellet.
- the cell pellet was suspended in 1 mL of MOPS (0) solution (MOPS medium not containing phosphorus component), and the suspension was centrifuged at 12000 rpm for 5 minutes. Thereafter, the supernatant was discarded to obtain a cell pellet. After the washing operation was performed once again, the obtained cell pellet was suspended in 1 mL of MOPS (0) solution, and then 100 ⁇ L of the suspension was added to 10 mL of MOPS-phosphorous acid (0.5 mM). Inoculated into a liquid medium and cultured at 45 ° C.
- MOPS (0) solution MOPS medium not containing phosphorus component
- the whole culture is transferred to a 50 mL tube, and the tube is centrifuged at 6000 rpm for 10 minutes. I went to. After centrifugation, the supernatant was discarded to obtain a cell pellet.
- ultrasonic disruption Digital sonifier, BRANSON
- BRANSON Digital sonifier
- OptimaTM TLX Ultracentrifuge, BECKMAN COULTER Ultracentrifugation was performed at 270,000 ⁇ g, 4 ° C. for 45 minutes.
- the supernatant after ultracentrifugation was collected, and the supernatant was used as a crude extract for measuring phosphite dehydrogenase activity.
- microorganisms that can grow under conditions of 45 ° C. and have the ability to produce NADH in a phosphorous acid-dependent manner were screened.
- the number of microorganisms screened was 5 strains.
- strains were classified based on the base sequence of 16S rRNA (16S ribosomal RNA), and the base sequence of the phosphite dehydrogenase gene of each strain was determined. A specific method will be described in detail below.
- chromosomal DNA was extracted from the strain 4506 obtained by the above screening, and 16s rRNA was used using the chromosomal DNA. The gene was amplified.
- the 16S rRNA gene was amplified by PCR.
- primers 1 and 2 described later were used as primers, and PCR reaction was performed using KOD-plus manufactured by Toyobo.
- KOD-plus manufactured by Toyobo.
- As specific PCR reaction conditions after incubation at 72 ° C. for 5 minutes, 95 ° C. for 1 minute denaturation step, 55 ° C. for 1 minute annealing step, and 72 ° C. for 1.5 minute extension step 3 A reaction cycle consisting of two steps was performed 30 times.
- Primer 1 5′-AGAGTTTGATCCTGGCTCAG-3 ′ (SEQ ID NO: 5)
- Primer 2 5′-GTCCCGCAACGAGCGCAAC-3 ′ (SEQ ID NO: 6)
- the base sequence of 16S rRNA amplified as described above was determined using DYEnamic ET Terminator (Applied Biosystems). The specific method followed the protocol attached to DYEnamic ET Terminator.
- the 4506 strains described above were classified by analyzing the base sequence of 16S rRNA determined as described above using Clustal W2, which is a phylogenetic tree creation tool. In addition, the specific method of the said analysis followed the protocol attached to Clustal W2.
- Fig. 1 shows the phylogenetic tree of 4506 strains screened. From this result, it was clarified that the strain 4506 is a bacterium belonging to the genus Ralstonia. Based on this, the strain was designated as Ralstonia sp. Named strain 4506.
- “Ralstonia sp. 4506” in FIG. 1 is the screened 4506 strain.
- “Ralstonia sp. 5_7_47FAA”, “Ralstonia metallidurans CH34”, “Alcaligenes faecalis WM2072” and “Pseudomonas stutzeri WM88” are well-known strains, and hydrous dephosphoric acid and dehydrogenase are also known. There was or was predicted the presence of a phosphite dehydrogenase gene and a phosphite dehydrogenase protein.
- “Ralstonia sp. 5_7_47FAA” was closely related to the 4506 strain in taxonomy, and the presence of its phosphite dehydrogenase gene was predicted. However, it has not been demonstrated whether or not the protein encoded by the phosphite dehydrogenase gene actually has phosphite dehydrogenase activity, and the base sequence on the 3 ′ end side of the phosphite dehydrogenase gene (in other words, For example, the amino acid sequence on the C-terminal side of the phosphite dehydrogenase protein) was unknown (see, for example, “http://www.ncbi.nlm.nih.gov/nuccore/308920199”).
- the internal region of the gene was obtained by PCR using primers designed based on the highly conserved region of the well-known phosphite dehydrogenase gene. And obtaining the full-length sequence of the phosphite dehydrogenase gene by obtaining the 5 ′ and 3 ′ regions of the gene by inverse PCR.
- the method will be described in more detail.
- degenerate primers (PTXD1 and PTXD2) were prepared based on two highly conserved amino acid sequences in known ptxD (positions 76-82 and 261-267 of Pstutzeri WM88). The base sequences of these degenerate primers are shown below.
- PTXD1 5′-AARGGNTAYGAYAAYTTYGAY-3 ′ (SEQ ID NO: 7)
- PTXD2 5′-RTCYTCCATYTCRTANACRTC-3 ′ (SEQ ID NO: 8) PCR was performed using the degenerate primer and the chromosome of strain 4506 as a template. As a result, an amplified DNA fragment of about 600 bp was obtained.
- the amplified DNA fragment was cloned into pGEM T-easy vector (Promega), and the base sequence of the amplified DNA fragment was determined. From the determined base sequence, it was confirmed that the amplified DNA fragment was the internal sequence of ptxD.
- primers for inverse PCR were prepared.
- the base sequences of these primers are shown below.
- PTXD3 5′-TCGTGGATGAGAATGCGGTGATAGC-3 ′ (SEQ ID NO: 9)
- PTXD4 5′-ATAGTCAGTTCAGCGGTCGGGATCG-3 ′ (SEQ ID NO: 10)
- 0.5 ⁇ g chromosome of 4506 strain was digested with 0.5 ⁇ L of restriction enzyme Pst I for 12 hours, then self-circularized with T4 DNA ligase, and further purified, An amount of 20% based on the total volume of the inverse PCR reaction solution was used.
- a DNA fragment of about 2.5 kb was obtained by inverse PCR using PTXD3 and PTXD4.
- primers for obtaining the full-length sequence of ptxD were prepared. The base sequences of these primers are shown below.
- PTXD5 5′-CGGGATCCGATGAAGCCCAAAGTCGTCCTC-3 ′
- PTXD6 5′-CGGAATTCGCCGCCTTTACTCCCGGATAC-3 ′
- PCR was performed using the chromosome of the strain 4506 as a template to amplify a DNA fragment of about 1 kb.
- the base sequence of the amplified DNA fragment was determined by the same method as described above.
- the base sequence of the phosphite dehydrogenase gene is shown in SEQ ID NO: 2.
- the amino acid sequence of the phosphite dehydrogenase protein encoded by the phosphite dehydrogenase gene is shown in SEQ ID NO: 1.
- the base sequence described in “http://www.ncbi.nlm.nih.gov/nuccore/308920199” described above completely matched the partial sequence of the base sequence shown in SEQ ID NO: 1.
- each of the above expression vectors was transformed into competent cell Rosetta2 (DE3) (Novagen).
- the transformant is inoculated into 200 mL of LB medium (containing 10 g of polypeptone, 5 g of yeast extract, and 5 g of NaCl per liter of medium) at 37 ° C. until OD 600 reaches 0.5. Cultured. Thereafter, IPTG (isopropyl thiogalactoside) was added to the culture to a concentration of 1 mM, and the culture was further continued at 28 ° C. for 3 hours.
- LB medium containing 10 g of polypeptone, 5 g of yeast extract, and 5 g of NaCl per liter of medium
- IPTG isopropyl thiogalactoside
- the culture was subjected to a centrifugation treatment at 6,000 rpm for 15 minutes, and the bacteria as a precipitate were collected.
- the bacteria were suspended in a disruption buffer (50 mM Tris-HCl (pH: 7.4), 50 mM NaCl), and then the suspension was subjected to ultrasonic treatment to disrupt the bacteria. Thereafter, Tween 20 (registered trademark) was added to the microbial disruption solution to a final concentration of 0.1%, and the mixture was allowed to stand on ice for 15 minutes.
- the crushing buffer containing the crushed bacteria is indicated as “T”.
- the crushing buffer containing the crushed bacteria was centrifuged at 15,000 rpm, 4 ° C., 15 minutes. After centrifugation, the supernatant was separated into a precipitate. In FIG. 2, the supernatant is indicated as “S”, and the precipitate is indicated as “I”.
- the supernatant is applied to a HisTrap column (manufactured by GE Healthcare), and a fusion protein in which a His tag is linked to the C-terminus of the phosphite dehydrogenase protein shown in SEQ ID NO: 1 according to the protocol attached to the column. Purified.
- disruption buffer (T), supernatant (S) and precipitate (I) containing disrupted bacteria are separated by SDS-PAGE, and then the acrylamide gel is subjected to CBB stain one (manufactured by Nacalai). Staining was performed to determine the amount of phosphite dehydrogenase protein.
- Each of purified PtxD 4506 and PtxD Pst was added to 50 mM MOPS buffer (pH 7.4) to a final concentration of 0.2 mg / mL to prepare an enzyme solution.
- 100 ⁇ L of the enzyme solution was put into a 1.5 mL capacity tube, and 100 ⁇ L of mineral oil was added to the enzyme solution to prevent evaporation. The tube was maintained at a temperature of 10 ° C. to 60 ° C. for 12 hours.
- PtxD Pst has the highest specific activity at about 35 ° C., and the specific activity rapidly decreases at temperatures lower than 35 ° C. and at temperatures higher than 35 ° C. It became clear to do. That is, it was revealed that PtxD Pst has a low optimum temperature (about 35 ° C.) and a very narrow temperature range suitable for the reaction.
- PtxD 4506 has the highest specific activity at about 50 ° C., and can maintain high specific activity in a wide temperature range even at temperatures lower than 50 ° C. or higher than 50 ° C. It was revealed. Specifically, PtxD 4506 has a high average specific activity at 35 ° C. to 55 ° C., a higher average specific activity at 40 ° C. to 52.5 ° C., and an average specific activity at 40 ° C. to 50 ° C. It became clear that the value was even higher. This indicates that the fusion protein PtxD 4506 can stably produce a large amount of substance even in a substance production process (for example, NADH or NADPH production process) that tends to be high temperature. This also indicates that the activity of the phosphite dehydrogenase is not lost even when the phosphite dehydrogenase is heated in the production process of the phosphite dehydrogenase protein.
- a substance production process for example, NADH or
- reaction rates of PtxD 4506 and PtxD Pst were calculated based on (Reaction Formula 1) described in the [Background Art] column.
- reaction system shown in (Reaction Scheme 1) 7.5 ⁇ g of fusion protein was used, and the NADH production rate was measured while changing the substrate (NAD + ) concentration from 0.5 microM to 200 microM. did.
- the reaction temperature of the fusion protein PtxD 4506 was 40 ° C.
- the reaction temperature of the fusion protein PtxD Pst was 28 ° C.
- the Km of PtxD 4506 was about 1/3 of the Km of PtxD Pst . Moreover, Vmax of PtxD 4506 was about 1.4 times PtxD Pst . The Kcat of PtxD 4506 was 237.4 (min ⁇ 1 ), and the Kcat of PtxD Pst was 169.6 (min ⁇ 1 ).
- the reaction solution was reacted for 60 minutes.
- about PtxD 4506 it reacted at 45 degreeC and about PtxD Pst, it reacted at 30 degreeC.
- OD 340 was measured.
- the relative value of OD 340 of each sample was calculated by setting the value of OD 340 of a liquid not containing protein (negative control) as 100.
- each experiment was performed 4 times or more, and the average value of the relative values in the 4 or 5 experiments was also calculated.
- FIG. 4 shows a graph of the numerical data in Table 2.
- PtxD 4506 the activity of PtxD 4506 was found to remain high even in the presence of arsenite, nitrate, sulfate or NaCl. This means that if phosphite dehydrogenase needs to be used in the presence of arsenite, nitrate, sulfate or NaCl (especially in the presence of arsenite, nitrate or sulfate), PtxD 4506 Is advantageous. Examples of cases where it is necessary to use phosphite dehydrogenase include, but are not limited to, NADH production, NADPH production, and phosphorous acid quantification.
- the present invention can be used in the field of manufacturing NADH or NADPH.
- the present invention can also be used in the field of quantifying phosphorous acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(a)配列番号1のアミノ酸配列からなるタンパク質。
(b)配列番号1のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸からなり、かつ、亜リン酸デヒドロゲナーゼ活性を有するタンパク質。
本実施の形態のタンパク質(亜リン酸デヒドロゲナーゼタンパク質)は、以下の(a)または(b)に記載のタンパク質である。つまり、
(a)配列番号1のアミノ酸配列からなるタンパク質、
(b)配列番号1のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸からなり、かつ、亜リン酸デヒドロゲナーゼ活性を有するタンパク質。
(c)配列番号2の塩基配列からなるDNA、
(d)配列番号2の塩基配列からなるDNAと相補的な塩基配列とストリンジェントな条件下でハイブリダイズし、かつ、亜リン酸デヒドロゲナーゼタンパク質をコードするDNA。
本実施形態の亜リン酸デヒドロゲナーゼタンパク質の製造方法は、以下の(a)または(b)のタンパク質を宿主内で発現させる工程と、上記宿主内で発現させたタンパク質を溶液中に可溶化させる工程と、を有する製造方法である。つまり、
(a)配列番号1のアミノ酸配列からなるタンパク質。
(b)配列番号1のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸からなり、かつ、亜リン酸デヒドロゲナーゼ活性を有するタンパク質。
(c)配列番号2の塩基配列からなるDNA。
(d)配列番号2の塩基配列からなるDNAと相補的な塩基配列とストリンジェントな条件下でハイブリダイズし、かつ、亜リン酸デヒドロゲナーゼタンパク質をコードするDNA。
本実施形態のNADHの製造方法は、本発明の亜リン酸デヒドロゲナーゼタンパク質の製造方法によって製造される亜リン酸デヒドロゲナーゼタンパク質を酵素として用いて、HPO3 2-とNAD+とH2Oとを反応させる方法である。なお、具体的な反応式については、〔背景技術〕の欄の(反応式1)を参照のこと。
本実施形態のキットは、NADHまたはNADPHを製造するためのキットである。
(c)配列番号2の塩基配列からなるDNA、
(d)配列番号2の塩基配列からなるDNAと相補的な塩基配列とストリンジェントな条件下でハイブリダイズし、かつ、亜リン酸デヒドロゲナーゼタンパク質をコードするDNA。
45℃の環境下においても生育し得、かつ、亜リン酸依存的なNADH生産能を有する微生物をスクリーニングした。以下に、スクリーニングの詳細について説明する。
上述した5菌株の粗抽出液中の亜リン酸デヒドロゲナーゼ活性はほぼ同程度であるとともに、当該5菌株は形態学的および生理学的に似ていた。それ故に、上記5菌株は、全て近縁種の菌であると考えられた。そこで、そこで、5菌株中で最も増殖に優れた菌株(4506株)を以降の解析に用いた。
・プライマー1:5’-AGAGTTTGATCCTGGCTCAG-3’(配列番号5)
・プライマー2:5’-GTCCCGCAACGAGCGCAAC -3’(配列番号6)
以上のようにして増幅した16S rRNAの塩基配列を、DYEnamic ET Terminator(アプライドバイオシステムズ社製)を用いて決定した。具体的な方法は、DYEnamic ET Terminatorに添付のプロトコールに従った。
・PTXD1:5’-AARGGNTAYGAYAAYTTYGAY-3’(配列番号7)
・PTXD2:5’-RTCYTCCATYTCRTANACRTC-3’(配列番号8)
上記縮重プライマーを用いて、4506株の染色体を鋳型としてPCRを行った。その結果、約600bpの増幅されたDNA断片を取得した。
・PTXD3:5’-TCGTGGATGAGAATGCGGTGATAGC-3’(配列番号9)
・PTXD4:5’-ATAGTCAGTTCAGCGGTCGGGATCG-3’(配列番号10)
インバースPCRのテンプレートとしては、4506株の0.5μgの染色体を0.5μLの制限酵素Pst Iを用いて12時間消化した後に、T4 DNA ligaseを用いて自己環状化させて更に精製したものを、インバースPCRの反応溶液の全体積に対して20%量用いた。PTXD3とPTXD4とを用いたインバースPCRによって、約2.5kbのDNA断片を得た。
・PTXD5:5’-CGGGATCCGATGAAGCCCAAAGTCGTCCTC-3’(配列番号11)
・PTXD6:5’-CGGAATTCGCCGCCTTTACTCCCGGATAC -3’(配列番号12)
PTXD5およびPTXD6を用いて、4506株の染色体を鋳型としてPCRを行い、約1kbのDNA断片を増幅した。増幅されたDNA断片の塩基配列を、上記と同様の方法にて決定した。
周知の方法によって、プラスミドであるpET21b(Novagen社製)へ、上述した配列番号2に示す塩基配列、または、P stutzeri WM88の亜リン酸デヒドロゲナーゼ遺伝子(配列番号4)を挿入した(配列番号4の塩基配列によってコードされているタンパク質のアミノ酸配列を配列番号3に示す)。これによって、配列番号1に示す亜リン酸デヒドロゲナーゼタンパク質のC末端にHisタグが連結している融合タンパク質(図2の「PtxD4506」参照)、または、P stutzeri WM88の亜リン酸デヒドロゲナーゼタンパク質のC末端にHisタグが連結している融合タンパク質(図2の「PtxDPst」参照)の発現ベクターを作成した。
〔3.大腸菌を用いた亜リン酸デヒドロゲナーゼタンパク質の発現〕にてHisTrapカラムを用いて精製したPtxD4506およびPtxDPstについて、耐熱性を検討した。以下に、耐熱性の測定方法について説明する。
〔3.大腸菌を用いた亜リン酸デヒドロゲナーゼタンパク質の発現〕にてHisTrapカラムを用いて精製したPtxD4506およびPtxDPstについて、反応速度を比較した。以下に、反応速度の測定方法について説明する。
〔3.大腸菌を用いた亜リン酸デヒドロゲナーゼタンパク質の発現〕にてHisTrapカラムを用いて精製したPtxD4506およびPtxDPstについて、様々な阻害剤が存在する環境下においても触媒活性を示し得るか否かを検討した。実験方法は、文献「Costas et al., Journal of Biological Chemistry, 2001, 276, 17429-17436」に記載の方法に従った。以下に、簡単に実験方法を説明する。
Claims (12)
- 以下の(a)または(b)に記載のタンパク質。
(a)配列番号1のアミノ酸配列からなるタンパク質。
(b)配列番号1のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸からなり、かつ、亜リン酸デヒドロゲナーゼ活性を有するタンパク質。 - 請求項1に記載のタンパク質をコードする遺伝子。
- 以下の(c)または(d)のDNAからなる、請求項2に記載の遺伝子。
(c)配列番号2の塩基配列からなるDNA。
(d)配列番号2の塩基配列からなるDNAと相補的な塩基配列とストリンジェントな条件下でハイブリダイズし、かつ、亜リン酸デヒドロゲナーゼタンパク質をコードするDNA。 - 請求項1に記載のタンパク質を宿主内で発現させる工程と、上記宿主内で発現させたタンパク質を溶液中に可溶化させる工程と、を有する亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 上記発現させる工程は、請求項2または3に記載の遺伝子を含むベクターを宿主へ導入する工程を包含する請求項4に記載の亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 上記可溶化させる工程は、上記タンパク質を発現している宿主を、0(w/v)または0(w/v)よりも多く0.1%(w/v)以下の界面活性剤、および、0(w/v)または0(w/v)よりも多く50mM以下のNaClの少なくとも一方を含有する溶液中で破砕する工程を包含することを特徴とする請求項4または5に記載の亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 上記界面活性剤は、Tween-20またはTriton-X100であることを特徴とする請求項6に記載の亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 上記タンパク質を発現している宿主、または、上記タンパク質を発現している宿主の破砕物を加熱する工程を包含することを特徴とする請求項4~7の何れか1項に記載の亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 上記加熱する工程は、上記タンパク質を発現している宿主、または、上記タンパク質を発現している宿主の破砕物を、40℃~50℃へ加熱する工程であることを特徴とする請求項8に記載の亜リン酸デヒドロゲナーゼタンパク質の製造方法。
- 請求項1に記載のタンパク質、または、請求項4~9の何れか1項に記載の方法によって製造される亜リン酸デヒドロゲナーゼタンパク質を酵素として用いて、HPO3 2-と、NAD+またはNADP+と、H2Oとを反応させることを特徴とするNADHまたはNADPHの製造方法。
- 上記反応は、40℃~50℃にて行われることを特徴とする請求項10に記載のNADHまたはNADPHの製造方法。
- 上記反応は、亜ヒ酸塩、硝酸塩、硫酸塩またはNaClの存在下で行われることを特徴とする請求項10または11に記載のNADHまたはNADPHの製造方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013512018A JP5892621B2 (ja) | 2011-04-26 | 2012-04-16 | 亜リン酸デヒドロゲナーゼタンパク質の製造方法およびその利用 |
US14/113,346 US9273290B2 (en) | 2011-04-26 | 2012-04-16 | Method for producing phosphite dehydrogenase protein and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011098670 | 2011-04-26 | ||
JP2011-098670 | 2011-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012147556A1 true WO2012147556A1 (ja) | 2012-11-01 |
Family
ID=47072078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/060293 WO2012147556A1 (ja) | 2011-04-26 | 2012-04-16 | 亜リン酸デヒドロゲナーゼタンパク質の製造方法およびその利用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9273290B2 (ja) |
JP (1) | JP5892621B2 (ja) |
WO (1) | WO2012147556A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014024998A1 (ja) | 2012-08-09 | 2014-02-13 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子をマーカーとした微生物の選択的培養方法 |
WO2015031441A2 (en) | 2013-08-27 | 2015-03-05 | Novogy, Inc. | Microorganisms engineered to use unconventional sources of phosphorus or sulfur |
JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6993660B2 (ja) | 2016-08-31 | 2022-02-15 | 国立大学法人広島大学 | 形質転換体、形質転換体の製造方法、および、当該形質転換体を用いた還元型リン化合物の有無の検出方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003213209A1 (en) * | 2002-02-22 | 2003-09-09 | The Board Of Trustees Of The University Of Illinois | Nad phosphite oxidoreductase a novel catalyst from bacteria for regeneration of nad(p)h |
CA2529063A1 (en) * | 2003-06-11 | 2004-12-16 | Biotechnology Research And Development Corporation | Phosphite dehydrogenase mutants for nicotinamide cofactor regeneration |
US20080148432A1 (en) * | 2005-12-21 | 2008-06-19 | Mark Scott Abad | Transgenic plants with enhanced agronomic traits |
WO2006074194A2 (en) * | 2005-01-05 | 2006-07-13 | Biotechnology Research And Development Corporation | Engineered phosphite dehydrogenase mutants for nicotinamide cofactor regeneration |
WO2008131215A2 (en) * | 2007-04-19 | 2008-10-30 | Biotechnology Research And Development Corporation | Engineered phosphite dehydrogenase mutants |
-
2012
- 2012-04-16 WO PCT/JP2012/060293 patent/WO2012147556A1/ja active Application Filing
- 2012-04-16 JP JP2013512018A patent/JP5892621B2/ja not_active Expired - Fee Related
- 2012-04-16 US US14/113,346 patent/US9273290B2/en not_active Expired - Fee Related
Non-Patent Citations (13)
Title |
---|
AKIO KURODA ET AL.: "Biotechnology for utilizing reduced phosphorus compounds", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR BIOTECHNOLOGY, vol. 63, 25 August 2011 (2011-08-25), JAPAN, pages 93 * |
DATABASE GENBANK 18 October 2010 (2010-10-18), "Definition: phosphonate dehydrogenase (NAD-dependent phosphitedehydrogenase) [Ralstonia sp. 5_7_47FAA]", retrieved from http://www.ncbi.nlm.nih. gov/protein/efp65990 accession no. FP65990 * |
DATABASE GENBANK 19 April 2011 (2011-04-19), "Definition:Alicycliphilus denitrificans K601, complete genome", retrieved from http://www.ncbi.nlm.nih.gov/nuccore/ 329308025?sat=14&satkey=10503485 accession no. P002657 * |
GARCIA COSTAS AM ET AL.: "Purification and Characterization of a Novel Phosphorus-oxidizing Enzyme from Pseudomonas stutzeri WM88", J. BIOL. CHEM., vol. 276, 2001, pages 17429 - 17436, XP002979983, DOI: doi:10.1074/jbc.M011764200 * |
HIROTA R ET AL.: "Isolation and characterization of a soluble and thermostable phosphite dehydrogenase from Ralstonia sp. Strain 4506", J. BIOSCI. BIOENG., vol. 113, no. 4, April 2012 (2012-04-01), pages 445 - 450, XP055181193, DOI: doi:10.1016/j.jbiosc.2011.11.027 * |
JOHANNES TW ET AL.: "Directed Evolution of a Thermostable Phosphite Dehydrogenase for NAD(P)H Regeneration", APPL. ENVIRON. MICROBIOL., vol. 71, no. 10, 2005, pages 5728 - 5734 * |
JOHANNES TW ET AL.: "Efficient Regeneration of NADPH Using an Engineered Phosphite Dehydrogenase", BIOTECHNOL. BIOENG., vol. 96, no. 1, 2007, pages 18 - 26 * |
MCLACHLAN MJ ET AL.: "Further improvement of phosphite dehydrogenase thermostability by saturation mutagenesis", BIOTECHNOLOGY AND BIOENGINEERING, vol. 99, no. ISSUE2, 2008, pages 268 - 274 * |
RYUICHI HIROTA ET AL.: "Construction and characterization of an NADH regeneration system using phosphite dehydrogenase", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR BIOTECHNOLOGY, vol. 63, 25 August 2011 (2011-08-25), JAPAN, pages 194 * |
TATSUYA FUJIBUCHI ET AL.: "Identification and characterization of phosphite dehydrogenase", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR BIOTECHNOLOGY, vol. 63, 25 August 2011 (2011-08-25), JAPAN, pages 193 * |
VRTIS JM ET AL.: "Phosphite Dehydrogenase: A Versatile Cofactor-Regeneration Enzyme", ANGEW. CHEM. INT. ED., vol. 41, no. 17, 2002, pages 3257 - 3259, XP002311088, DOI: doi:10.1002/1521-3773(20020902)41:17<3257::AID-ANIE3257>3.0.CO;2-N * |
WOODYER R ET AL.: "Mechanistic investigation of a highly active phosphite dehydrogenase mutant and its application for NADPH regeneration", FEBS J., vol. 272, no. 15, 2005, pages 3816 - 3827, XP055033097, DOI: doi:10.1111/j.1742-4658.2005.04788.x * |
WOODYER R ET AL.: "Optimizing a biocatalyst for improved NAD(P)H regeneration: directed evolution of phosphite dehydrogenase", COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol. 9, no. 4, 2006, pages 237 - 245 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014024998A1 (ja) | 2012-08-09 | 2014-02-13 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子をマーカーとした微生物の選択的培養方法 |
JP2017195907A (ja) * | 2012-08-09 | 2017-11-02 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子をマーカーとした微生物の選択的培養方法 |
EP3395940A1 (en) | 2012-08-09 | 2018-10-31 | Hiroshima University | Method for selectively culturing microorganism using phosphite dehydrogenase gene as marker |
WO2015031441A2 (en) | 2013-08-27 | 2015-03-05 | Novogy, Inc. | Microorganisms engineered to use unconventional sources of phosphorus or sulfur |
CN105658801A (zh) * | 2013-08-27 | 2016-06-08 | 诺沃吉公司 | 经工程改造以利用非常规的磷或硫源的微生物 |
EP3039149A4 (en) * | 2013-08-27 | 2017-05-10 | Novogy Inc. | Microorganisms engineered to use unconventional sources of phosphorus or sulfur |
AU2014311318B2 (en) * | 2013-08-27 | 2017-11-02 | Ginkgo Bioworks, Inc. | Microorganisms engineered to use unconventional sources of phosphorus or sulfur |
US10174296B2 (en) | 2013-08-27 | 2019-01-08 | Novogy, Inc. | Microorganisms engineered to use unconventional sources of phosphorous or sulfur |
US11535829B2 (en) | 2013-08-27 | 2022-12-27 | Ginkgo Bioworks, Inc. | Microorganisms engineered to use unconventional sources of phosphorous or sulfur |
JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2012147556A1 (ja) | 2014-07-28 |
US20140051134A1 (en) | 2014-02-20 |
US9273290B2 (en) | 2016-03-01 |
JP5892621B2 (ja) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5892621B2 (ja) | 亜リン酸デヒドロゲナーゼタンパク質の製造方法およびその利用 | |
JP5641738B2 (ja) | 新規なグルコースデヒドロゲナーゼ | |
US9896705B2 (en) | L-arabinose isomerase variants with improved conversion activity and method for production of D-tagatose using them | |
Duffaud et al. | Isolation and characterization of Thermococcus barossii, sp. nov., a hyperthermophilic archaeon isolated from a hydrothermal vent flange formation | |
JP3910142B2 (ja) | 耐熱性リボヌクレアーゼh | |
JP2007189905A (ja) | 好アルカリ性サイクロデキストラン合成酵素遺伝子を含有するdna、組み換え体dna、および好アルカリ性サイクロデキストラン合成酵素の製造法 | |
WO2018114576A1 (en) | Glutathione reductase | |
Yoon et al. | Cloning, Expression, and Characterization of UDP-glucose Pyrophosphorylase from Sphingomonas chungbukensis DJ77 | |
JP4816103B2 (ja) | グリセロールキナーゼ改変体 | |
JP2005500852A (ja) | ビタミンb12を製造する方法 | |
Ozer Uyar et al. | Cloning and expression of trehalose‐6‐phosphate synthase 1 from Rhizopus oryzae | |
JP3463951B2 (ja) | 耐熱性ピログルタミルペプチダーゼ及びその遺伝子 | |
JP4415247B2 (ja) | 新規なグリセロールキナーゼ、該遺伝子及び該遺伝子を用いたグリセロールキナーゼの製造法 | |
JP2005296010A (ja) | 2−イソプロピルリンゴ酸シンターゼ活性を有する新規耐熱性タンパク質 | |
JP2003144144A (ja) | 菌体または菌体処理物を含有する液体の保存方法 | |
KR100707989B1 (ko) | 남세균 시네코시스티스 속의 이소코리스메이트 합성효소 유전자를 이용하여 코리스메이트로부터 이소코리스메이트를 생합성하는 방법 | |
JP6171406B2 (ja) | Dna修飾酵素およびその遺伝子 | |
JP4280827B2 (ja) | アセチルグルタミン酸キナーゼ活性を有する新規耐熱性タンパク質 | |
JP2006288400A (ja) | 耐熱性リボヌクレアーゼh | |
KR101296882B1 (ko) | 써모코커스 와이오타푸엔시스 균주 유래의 dna 중합효소 변이체들 및 이의 이용 | |
JP2014168404A (ja) | 耐熱性1,3−βガラクトシル−N−アセチルヘキソサミンホスホリラーゼ | |
JP2008092814A (ja) | メバロン酸リン酸化酵素活性を有する新規耐熱性タンパク質 | |
JP2005296008A (ja) | 水銀レダクターゼ活性を有する新規耐熱性タンパク質 | |
JP2006238830A (ja) | 新規乳酸脱水素酵素遺伝子及び乳酸の製造法 | |
JP2007129908A (ja) | システインプロテアーゼ及びその利用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12775990 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14113346 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013512018 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12775990 Country of ref document: EP Kind code of ref document: A1 |